Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Condylomata Acuminata 1

Interventions

aldesleukin 2Adoptive Transfer 2trastuzumab deruxtecan 1talazoparib 1liposomal doxorubicin 1fludarabine 1dostarlimab 1belzutifan 1apixaban 1Vaccines, Synthetic 1Therapeutic Touch 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Rivaroxaban 1Radiotherapy 1Radiation 1Papillomavirus Vaccines 1Paclitaxel 1Observation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Imiquimod 1Hysterectomy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vaginal Neoplasms × Vaccines, Synthetic × Clear all
NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
8,000 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡